A New Direction in Endometrial Cancer Therapy-PD-1 and PD-L1 Immune Checkpoint Inhibitors-Where Will It Take Us?

ABSTRACT: Background: Endometrial cancer (EC) remains a significant therapeutic challenge due to its rising incidence and a five-year survival rate of only 16% in cases of metastases or advanced disease when using classical therapy methods. For this reason, more effective methods of treatment are still sought, which currently focus on immunotherapy with the use of PD-1 and PD-L1 inhibitors (ICI), which is the subject of our article. Methods: Articles published in the databases: Pubmed, Web of Science, and ClinicalTrials.gov in the years 2019-2024 were analyzed. Results: ICIs can be used in monotherapy as well as in combination therapy, but it is the latter option that significantly prolongs the median PFS, especially the combination of ICI with PARP inhibitors. Among the availab

SUBMITTER: Mielnicka N 

PROVIDER: S-EPMC12693102 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature